{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:28:11Z","timestamp":1787059691086,"version":"build-2736575974"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) arise from overlapping metabolic stress, gut-derived inflammatory input, immune activation, and fibrotic remodeling. Bile acids participate in cholesterol metabolism and lipid absorption, and they also regulate metabolic, intestinal barrier, immune, and inflammatory responses through farnesoid X receptor (FXR), G protein-coupled bile acid receptor 1 (TGR5\/GPBAR1), fibroblast growth factor 19 (FGF19), and related signaling pathways. Accordingly, bile acids may constitute an important interface linking intrahepatic metabolic abnormalities with gut\u2013liver inflammatory crosstalk, although many human findings remain associative and require cautious mechanistic interpretation. This review summarizes bile acid-axis dysregulation in MASLD\/MASH, focusing on intrahepatic bile acid synthesis and transport, microbiota-mediated bile acid pool remodeling, intestinal barrier disruption, and the intrahepatic inflammatory-fibrotic niche. We propose that bile acid dysregulation should be interpreted beyond simple increases or decreases in total bile acid levels. Instead, it may reflect a systemic mismatch among bile acid pool composition, compartmental distribution, microbial transformation, and receptor-mediated signaling output. Future studies should integrate multi-compartment bile acid profiling with microbial enzyme activity, intestinal barrier assessment, and tissue-specific receptor signaling to support mechanism-based stratification, treatment-response monitoring, and rational combination strategies.<\/jats:p>","DOI":"10.3389\/fmed.2026.1912000","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:59:53Z","timestamp":1787057993000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Bile acid-axis dysregulation in MASLD\/MASH progression: from metabolic mismatch to inflammatory-fibrotic remodeling"],"prefix":"10.3389","volume":"13","author":[{"given":"Yang","family":"Du","sequence":"first","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine, Harbin","place":["Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qi","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine, Harbin","place":["Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunze","family":"Shi","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine, Harbin","place":["Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine, Harbin","place":["Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopei","family":"Shi","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine, Harbin","place":["Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine, Harbin","place":["Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fang","sequence":"additional","affiliation":[{"name":"Graduate School, Heilongjiang University of Chinese Medicine, Harbin","place":["Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Hu","sequence":"additional","affiliation":[{"name":"Basic Medical College of Heilongjiang University of Chinese Medicine, Harbin","place":["Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell."},{"key":"B8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"100477","DOI":"10.1016\/j.jhepr.2022.100477","article-title":"Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease","volume":"4","author":"McGlinchey","year":"2022","journal-title":"JHEP Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1152\/physrev.00049.2019","article-title":"Molecular physiology of bile acid signaling in health, disease, and aging","volume":"101","author":"Perino","year":"2021","journal-title":"Physiol Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"949033","DOI":"10.3389\/fimmu.2022.949033","article-title":"Bile acids in immunity: Bidirectional mediators between the host and the microbiota","volume":"13","author":"Godlewska","year":"2022","journal-title":"Front Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1084\/jem.20171965","article-title":"Bile acids in glucose metabolism in health and disease","volume":"215","author":"Shapiro","year":"2018","journal-title":"J Exp Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","article-title":"Bile acids and the gut microbiota: metabolic interactions and impacts on disease","volume":"21","author":"Collins","year":"2023","journal-title":"Nat Rev Microbiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40168-021-01101-1","article-title":"Review: microbial transformations of human bile acids","volume":"9","author":"Guzior","year":"2021","journal-title":"Microbiome."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1007581","DOI":"10.1371\/journal.ppat.1007581","article-title":"Bile salt hydrolases: Gatekeepers of bile acid metabolism and host-microbiome crosstalk in the gastrointestinal tract","volume":"15","author":"Foley","year":"2019","journal-title":"PLoS Pathog."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1136\/gutjnl-2020-323071","article-title":"Gut microbiota-derived metabolites as central regulators in metabolic disorders","volume":"70","author":"Agus","year":"2021","journal-title":"Gut."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001539.","article-title":"Bile acid signaling in MASLD: From pathogenesis to therapeutic applications","author":"Simbrunner","year":"2025","journal-title":"Hepatology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/microorganisms14020471","article-title":"The gut-liver axis in MASLD: from host-microbiome crosstalk to precision therapeutics","volume":"14","author":"Zhou","year":"2026","journal-title":"Microorganisms."},{"key":"B19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.5009\/gnl240539","article-title":"Gut-Liver Axis: The role of intestinal microbiota and their metabolites in the progression of metabolic dysfunction-associated steatotic liver disease","volume":"19","author":"Cui","year":"2025","journal-title":"Gut Liver."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1093420","DOI":"10.3389\/fmicb.2022.1093420","article-title":"The 7-alpha-dehydroxylation pathway: an integral component of gut bacterial bile acid metabolism and potential therapeutic target","volume":"13","author":"Wise","year":"2022","journal-title":"Front Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2017709118","DOI":"10.1073\/pnas.2017709118","article-title":"Lactobacillus bile salt hydrolase substrate specificity governs bacterial fitness and host colonization","volume":"118","author":"Foley","year":"2021","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B23","doi-asserted-by":"publisher","first-page":"G440","DOI":"10.1152\/ajpgi.00322.2009","article-title":"The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance","volume":"298","author":"Schreuder","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jhep.2024.08.012","article-title":"Dysglycemia and liver lipid content determine the relationship of insulin resistance with hepatic OXPHOS capacity in obesity","volume":"82","author":"Kahl","year":"2025","journal-title":"J Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1639064","DOI":"10.3389\/fendo.2025.1639064","article-title":"Metabolic and genetic mechanisms of metabolic dysfunction-associated steatotic liver disease: an integrative perspective from molecular pathways to clinical challenges","volume":"16","author":"Ma","year":"2025","journal-title":"Front Endocrinol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.3390\/molecules30153066","article-title":"Multifaceted Interactions Between Bile Acids, Their Receptors, and MASH: From Molecular Mechanisms to Clinical Therapeutics","volume":"30","author":"Tang","year":"2025","journal-title":"Molecules."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e152961","DOI":"10.1172\/JCI152961","article-title":"Haploinsufficiency of CYP8B1 associates with increased insulin sensitivity in humans","volume":"132","author":"Zhong","year":"2022","journal-title":"J Clin Invest."},{"key":"B29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3390\/biom14070841","article-title":"Bile Acids as Emerging Players at the Intersection of Steatotic Liver Disease and Cardiovascular Diseases","volume":"14","author":"Bilson","year":"2024","journal-title":"Biomolecules."},{"key":"B30","doi-asserted-by":"publisher","first-page":"11530","DOI":"10.3390\/ijms262311530","article-title":"Lithocholic Acid Species: Metabolism, Signaling Pathways, and Clinical Significance in Enterohepatic Diseases","volume":"26","author":"Leng","year":"2025","journal-title":"Int J Mol Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"E644","DOI":"10.1152\/ajpendo.00346.2024","article-title":"Plasma and fecal bile acids profiles in metabolic dysfunction-associated steatotic liver disease with advanced fibrosis","volume":"329","author":"Pradeau","year":"2025","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1640873","DOI":"10.3389\/fphar.2025.1640873","article-title":"Critical review of natural products driven correction of bile acid dysregulation: a therapeutic strategy for nonalcoholic fatty liver disease","volume":"16","author":"Peng","year":"2025","journal-title":"Front Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/pro.3484","article-title":"Bile salt hydrolases: structure and function, substrate preference, and inhibitor development","volume":"27","author":"Dong","year":"2018","journal-title":"Protein Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"100265","DOI":"10.1016\/j.cellin.2025.100265","article-title":"Microbiota-derived bile acid metabolic enzymes and their impacts on host health","volume":"4","author":"Ma","year":"2025","journal-title":"Cell Insight."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.csbj.2019.07.012","article-title":"Diversity of Bacteria Exhibiting Bile Acid-inducible 7\u03b1-dehydroxylation Genes in the Human Gut","volume":"17","author":"Vital","year":"2019","journal-title":"Comput Struct Biotechnol J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-020-2396-4","article-title":"A metabolic pathway for bile acid dehydroxylation by the gut microbiome","volume":"582","author":"Funabashi","year":"2020","journal-title":"Nature."},{"key":"B37","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41586-024-07017-8","article-title":"Bile salt hydrolase acyltransferase activity expands bile acid diversity","volume":"626","author":"Guzior","year":"2024","journal-title":"Nature."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2608437","DOI":"10.1080\/19490976.2025.2608437","article-title":"Bile salt hydrolase activity as a rational target for MASLD therapy","volume":"18","author":"Jones","year":"2026","journal-title":"Gut Microbes."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.3390\/cells12141888","article-title":"Bile Acids, Intestinal Barrier Dysfunction, and Related Diseases","volume":"12","author":"Shi","year":"2023","journal-title":"Cells."},{"key":"B40","doi-asserted-by":"publisher","first-page":"101148","DOI":"10.1016\/j.jhepr.2024.101148","article-title":"A gut microbiota-independent mechanism shapes the bile acid pool in mice with MASH","volume":"6","author":"Gillard","year":"2024","journal-title":"JHEP Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile acid metabolites control T(H)17 and T(reg) cell differentiation","volume":"576","author":"Hang","year":"2019","journal-title":"Nature."},{"key":"B42","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-019-1865-0","article-title":"Microbial bile acid metabolites modulate gut RORgamma(+) regulatory T cell homeostasis","volume":"577","author":"Song","year":"2020","journal-title":"Nature."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.03.034","article-title":"Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway","author":"Nie","year":"2024","journal-title":"Cell."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2331460","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: the role of gut homeostasis in metabolic-associated steatotic liver disease (MASLD)","volume":"16","author":"Benede-Ubieto","year":"2024","journal-title":"Gut Microbes."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1966263","DOI":"10.1080\/19490976.2021.1966263","article-title":"Deprivation of dietary fiber in specific-pathogen-free mice promotes susceptibility to the intestinal mucosal pathogen Citrobacter rodentium","volume":"13","author":"Neumann","year":"2021","journal-title":"Gut Microbes."},{"key":"B46","doi-asserted-by":"publisher","first-page":"6377","DOI":"10.3390\/cimb46070381","article-title":"The Role of microbiota-related co-metabolites in MASLD progression: a narrative review","volume":"46","author":"Martin-Grau","year":"2024","journal-title":"Curr Issues Mol Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"eabo2794","DOI":"10.1126\/sciadv.abo2794","article-title":"Inhibition of microbial deconjugation of micellar bile acids protects against intestinal permeability and liver injury","volume":"8","author":"Li","year":"2022"},{"key":"B48","doi-asserted-by":"publisher","first-page":"166480","DOI":"10.1016\/j.bbadis.2022.166480","article-title":"Macrophage-specific MyD88 deletion and pharmacological inhibition prevents liver damage in non-alcoholic fatty liver disease via reducing inflammatory response","volume":"1868","author":"Yang","year":"2022","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/s42255-025-01318-6","article-title":"Multi-omic analysis reveals transkingdom gut dysbiosis in metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"Kim","year":"2025","journal-title":"Nat Metab."},{"key":"B50","doi-asserted-by":"publisher","first-page":"700058","DOI":"10.3389\/fnut.2021.700058","article-title":"Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents","volume":"8","author":"Tokuhara","year":"2021","journal-title":"Front Nutr."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e0063425","DOI":"10.1128\/msystems.00634-25","article-title":"Microbial changes resulting from VSG attenuate MASLD by modulating bile acid metabolism and the intestinal FXR-FGF19 axis","volume":"10","author":"Xia","year":"2025","journal-title":"mSystems."},{"key":"B52","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s10620-020-06715-3","article-title":"Bile acid signaling in inflammatory bowel diseases","volume":"66","author":"Fiorucci","year":"2021","journal-title":"Dig Dis Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jhep.2023.12.024","article-title":"Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8(+) T cells","volume":"80","author":"Zheng","year":"2024","journal-title":"J Hepatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/biom13091356","article-title":"Alterations in circulating bile acids in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"13","author":"Lai","year":"2023","journal-title":"Biomolecules."},{"key":"B55","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/biom15040469","article-title":"The role of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and other metabolic diseases","volume":"15","author":"Munte","year":"2025","journal-title":"Biomolecules."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e2410602","DOI":"10.1002\/advs.202410602","article-title":"Conjugated lithocholic acid activates hepatic tgr5 to promote lipotoxicity and MASLD-MASH transition by disrupting carnitine biosynthesis","volume":"12","author":"Lian","year":"2025","journal-title":"Adv Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"108626","DOI":"10.1016\/j.celrep.2020.108626","article-title":"Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH","volume":"34","author":"Daemen","year":"2021","journal-title":"Cell Rep."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","article-title":"Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis","volume":"52","author":"Seidman","year":"2020","journal-title":"Immunity."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.cmet.2024.05.008","article-title":"Reactive oxygen species regulation by NCF1 governs ferroptosis susceptibility of Kupffer cells to MASH","volume":"36","author":"Zhang","year":"2024","journal-title":"Cell Metab."},{"key":"B60","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jhep.2024.10.044","article-title":"Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease","volume":"82","author":"Kim","year":"2025","journal-title":"J Hepatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e16125","DOI":"10.1111\/liv.16125","article-title":"Spatial and single-cell transcriptomics reveals the regional division of the spatial structure of MASH fibrosis","volume":"45","author":"Li","year":"2025","journal-title":"Liver Int."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.018","article-title":"Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches","author":"Guilliams","year":"2022","journal-title":"Cell."},{"key":"B63","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature."},{"key":"B64","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.4049\/jimmunol.178.8.5288","article-title":"Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis","volume":"178","author":"Fallowfield","year":"2007","journal-title":"J Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1038\/s41588-025-02407-8","article-title":"Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease","volume":"57","author":"Li","year":"2025","journal-title":"Nat Genet."},{"key":"B66","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41467-024-55325-4","article-title":"Spatial transcriptomics of healthy and fibrotic human liver at single-cell resolution","volume":"16","author":"Watson","year":"2025","journal-title":"Nat Commun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41746-026-02352-8","article-title":"Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH","volume":"9","author":"Wen","year":"2026","journal-title":"NPJ Digit Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"116915","DOI":"10.1016\/j.celrep.2025.116915","article-title":"Scar-associated endothelial-stellate cellular crosstalk drives fibrosis resolution in MASH","volume":"45","author":"Li","year":"2026","journal-title":"Cell Rep."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1136\/gutjnl-2024-332105","article-title":"Spatial single-cell omics: new insights into liver diseases","volume":"75","author":"Suo","year":"2026","journal-title":"Gut."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/j.cgh.2023.03.041","article-title":"Clinical Trial Landscape in NASH","volume":"21","author":"Harrison","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"54","DOI":"10.17925\/EE.2024.20.2.8","article-title":"Role of obeticholic acid, a farnesoid x receptor agonist, in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"20","author":"Kamrul-Hasan","year":"2024","journal-title":"touchREV Endocrinol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J Hepatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology."},{"key":"B75","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"et al. Semaglutide 24 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J Clin Invest."},{"key":"B82","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.3390\/ijms24044050","article-title":"Impact of vancomycin treatment and gut microbiota on bile acid metabolism and the development of non-alcoholic steatohepatitis in mice","volume":"24","author":"Kasai","year":"2023","journal-title":"Int J Mol Sci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e2307981","DOI":"10.1002\/advs.202307981","article-title":"Antibiotic-induced gut microbiota dysbiosis modulates host transcriptome and MA epitranscriptome via bile acid metabolism","volume":"11","author":"Yang","year":"2024","journal-title":"Adv Sci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"G42","DOI":"10.1152\/ajpgi.00017.2023","article-title":"Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease","volume":"325","author":"Kaufmann","year":"2023","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1129904","DOI":"10.3389\/fmicb.2023.1129904","article-title":"Bifidobacterium-derived short-chain fatty acids and indole compounds attenuate nonalcoholic fatty liver disease by modulating gut-liver axis","volume":"14","author":"Yoon SJ Yu","year":"2023","journal-title":"Front Microbiol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12967-025-07478-z","article-title":"The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial","volume":"24","author":"Won","year":"2025","journal-title":"J Transl Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"113325","DOI":"10.1016\/j.nut.2026.113325","article-title":"Effects of multistrain probiotic supplementation on hepatic function and anthropometric parameters in patients with metabolic dysfunction-associated steatotic liver disease: a double-blind, randomized controlled trial","volume":"151","author":"Moszak","year":"2026","journal-title":"Nutrition."},{"key":"B88","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.apsb.2023.11.011","article-title":"Mechanism of action of the bile acid receptor TGR5 in obesity","volume":"14","author":"Lun","year":"2024","journal-title":"Acta Pharm Sin B."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2024.06.014","article-title":"A small intestinal bile acid modulates the gut microbiome to improve host metabolic phenotypes following bariatric surgery","author":"Chen","year":"2024","journal-title":"Cell Host Microbe."},{"key":"B92","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/HC9.0000000000000574","article-title":"Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767","author":"Ramachandran","year":"2024","journal-title":"Hepatol Commun."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2304157","DOI":"10.1080\/19490976.2024.2304157","article-title":"Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus","volume":"16","author":"Forlano","year":"2024","journal-title":"Gut Microbes."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1912000\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:59:54Z","timestamp":1787057994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1912000\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":93,"alternative-id":["10.3389\/fmed.2026.1912000"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1912000","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1912000"}}